Scientists have uncovered how a key type of immune cell adapts its behavior depending on the type of infection, paving the ...
The U.S. Food and Drug Administration has approved Opzelura cream 1.5 percent (ruxolitinib) for children ages 2 to 11 years ...
IMPACT-HTN, a novel initiative to modernize hypertension care, has been launched by Idorsia at Stanford Hypertension Center and Duke Heart Center.
Pharmaceutical Technology on MSN
Regeneron’s Evkeeza gains FDA approval for young HoFH patients
The decision to broaden the antibody’s indication was based on clinical efficacy and safety data from six children.
A procedure that may assist couples is intrauterine insemination (IUI). This is an assisted reproduction procedure where sperm are placed directly into the uterus at a specific time in the woman's ...
Science has confirmed what sports lovers have always known from experience: exercise is good for the brain. It increases ...
The ACR recently issued the first formal international consensus guidance statement on diagnosing and managing VEXAS syndrome.
National AI usage among businesses is 9.2%, with a projected increase to 11.6% in six months. Utah leads state AI business adoption at 15.7%%; Delaware's projected rate is highest at 19.1%.
WILMINGTON, DE — Incyte (Nasdaq: INCY) announced that the U.S. Food and Drug Administration has approved Opzelura (ruxolitinib) cream 1.5% for children as young as two with mild to moderate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback